Ranbaxy Q1 net zooms to Rs 1,247 cr
10 May 2012 6:04 AM GMT
Drug major Ranbaxy Laboratories on Wednesday said its consolidated net profit surged over four-fold to Rs 1,246.76 crore during the first quarter ended 31 March 2012, over the same period of previous year.
The company had posted a profit of Rs 304.38 crore during the quarter ended 31 March 2011, Ranbaxy Laboratories said in a filing to the BSE.
Net sales of the company rose to Rs 3,695.40 crore for the quarter ended 31 March 2012, as against Rs 2,141.49 crore during the same period of previous year.
On a standalone basis, the company posted a net profit of Rs 827.23 crore for the first quarter, while it had a net loss of Rs 52.9 crore in the corresponding period of last year.
The company’s net sales on standalone basis rose to Rs 1,810.22 crore during the first quarter, as against Rs 1,054.92 crore in the same period of last year.
Commenting on results, Ranbaxy CEO and managing director Arun Sawhney said: 'The focus on key products and markets, while maintaining emphasis on further strengthening quality and compliance standards, has had a positive impact on the performance of Ranbaxy during the quarter.’
Shares of Ranbaxy were trading at Rs 514.20 on the BSE in late afternoon trade, up 4.15 per cent from its previous close.
The company had posted a profit of Rs 304.38 crore during the quarter ended 31 March 2011, Ranbaxy Laboratories said in a filing to the BSE.
Net sales of the company rose to Rs 3,695.40 crore for the quarter ended 31 March 2012, as against Rs 2,141.49 crore during the same period of previous year.
On a standalone basis, the company posted a net profit of Rs 827.23 crore for the first quarter, while it had a net loss of Rs 52.9 crore in the corresponding period of last year.
The company’s net sales on standalone basis rose to Rs 1,810.22 crore during the first quarter, as against Rs 1,054.92 crore in the same period of last year.
Commenting on results, Ranbaxy CEO and managing director Arun Sawhney said: 'The focus on key products and markets, while maintaining emphasis on further strengthening quality and compliance standards, has had a positive impact on the performance of Ranbaxy during the quarter.’
Shares of Ranbaxy were trading at Rs 514.20 on the BSE in late afternoon trade, up 4.15 per cent from its previous close.
Next Story
